Microarrayed allergen molecules: diagnostic gatekeepers for allergy treatment

R. Hiller, S. Laffer, C. Harwanegg, M. Huber, W.M. Schmidt, A. Twardosz, B. Barletta, W.M. Becker, K. Blaser, H. Breiteneder, A. Chapman, R. Crameri, M. Duchene, F. Ferreira, H. Fiebig, K. Hoffmann-Sommergruber, T.P. King, T. Kleber-Janke, V.P. Kurup, S.B. LehrerJ. Lidholm, U. Muller, C. Pini, G. Reese, O. Scheiner, A. Scheynius, H-D. Shen, S. Spitzauer, R. Suck, I. Swoboda, Wayne Thomas, R. Tinghino, M. Van Hage-Hamsten, T. Virtanen, D. Kraft, M.W. Muller, R. Valenta

Research output: Contribution to journalArticlepeer-review

405 Citations (Scopus)


Type I allergy is an immunoglobulin E (IgE)-mediated hypersensitivity disease affecting more than 25% of the population. Currently, diagnosis of allergy is performed by provocation testing and IgE serology using allergen extracts. This process defines allergen-containing sources but cannot identify the disease-eliciting allergenic molecules. We have applied microarray technology to develop a miniaturized allergy test containing 94 purified allergen molecules that represent the most common allergen sources. The allergen microarray allows the determination and monitoring of allergic patients' IgE reactivity profiles to large numbers of disease-causing allergens by using single measurements and minute amounts of serum. This method may change established practice in allergy diagnosis, prevention, and therapy. In addition, microarrayed antigens may be applied to the diagnosis of autoimmune and infectious diseases.
Original languageEnglish
Pages (from-to)414-416
JournalFASEB Journal
Publication statusPublished - 2002


Dive into the research topics of 'Microarrayed allergen molecules: diagnostic gatekeepers for allergy treatment'. Together they form a unique fingerprint.

Cite this